KIDNEYS AND URETERS
is necessary to differentiate between them. A hematoma initially is hyperechoic,but gradually becomes hypoechoic and eventually anechoic.
A seroma, urinoma, and lymphocele are all hypointense on T1and hyperintense on T2weighted MRI. Significant urinomas usually require reoperation.
Lymphoceles develop from the disruption of pelvic lymphatics. They tend to become multiseptated. Therapy of these posttransplant lymphoceles includes open or laparoscopic marsupialization, percutaneous drainage, and percutaneous injection of a sclerotic agent. External drainage has a high failure rate, but percutaneous sclerotherapy using a povidoneiodine agent is a simple technique and has had considerable application; recurrent lymphoceles can be retreated percutaneously. Laparoscopic marsupialization with internal drainage is feasible, and effective therapy for posttransplant lymphoceles but is more invasive. Intraoperative US guidance is often helpful.
Stones
The frequency of urinary calculi in a transplanted kidney ranges up to 3%, a prevalence greater than in the general population. About half of these stones are composed of urate. Not all filling defects are stones. Blood clots, fungus balls, or sloughed papillae are also encountered.
Lymphoproliferative Disorder/Neoplasms
Renal transplant patients are immunosuppressed and, not surprisingly, are at an increased risk of developing neoplasms. Epstein-Barr virus infection is believed to be responsible for most of this increased risk. To put this issue in perspective, approximately 1% of renal transplant patients develop a lymphoproliferative disorder, considerably more than the general population. A retrospective Italian study found 15 cancers in 11 posttransplant patients, including skin cancers, Kaposi’s sarcomas, renal carcinomas, transitional cell carcinoma, and even colon cancer (141); the mean time of immunosuppression until tumor detection was 45 months, and, surprisingly, no lymphomas or female genital tract cancers were found.
Over the years, the sites of lymphoproliferative disorder involvement in renal trans-
plant patients have changed considerably; central nervous system involvement predominated initially, during the cyclosporine era thoracic and abdominal sites were more common, while isolated involvement of the transplanted kidney is now more evident. Currently lymphoproliferative disorders most often present as solitary or multiple tumors, often limited either to the allograft or allograft hilum (142); most are extranodal in location. Newer immunosuppression agents are evolving, and the type of neoplasms encountered in different studies reflects, in part, the immunosuppressive approach used.
Lymphoproliferation ranges from a nonspecific mild adenopathy to malignant lymphoma. B-cell non-Hodgkin’s lymphoma is most common, but other lymphomas are also encountered. In general, these lymphomas tend to be more aggressive than their counterparts in nonimmunosuppressed individuals.
Transplant patients develop renal cell carcinomas in the native kidneys and in the renal allograft and ovarian carcinomas. No significant relationship exists between the prevalence of renal cell carcinoma and the presence of acquired cystic kidney disease, patient age, type and duration of dialysis, or drugs used. Screening of the native kidneys appears reasonable in patients undergoing US of a renal allograft.
Those Australian and New Zealand Dialysis and Transplant Registry patients who had renal transplantation as a result of analgesic nephropathy were found to be at an increased risk of developing posttransplant transitional cell carcinomas of the upper urinary tracts compared to patients undergoing transplantation for other causes of renal failure (143); their tumors tend to be of a higher grade and stage, and they have a worse outcome than do other transplant patients. Screening with urinalysis and voided urine cytology does not appear to be reliable in detecting upper renal tract malignancies. Annual cystoscopy and retrograde ureteral catheterization with washings, brushings, and radiologic imaging were advocated in these patients. The patients should also be screened before transplantation.
Both bladder nephrogenic metaplasia and nephrogenic adenomas develop in these patients; these benign tumors, considered to be without malignant potential, have a relatively high relapse rate. Their long-term course in